Fed’s Goolsbee Warns Inflation Remains Elevated, Signals Caution on Rate Cuts 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves 
Wall Street Surges to Record Highs Amid Strong Earnings and Economic Stability 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Gold Prices Hold Steady as Iran War and Interest Rate Outlook Weigh on Markets 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Oil Prices Rise Amid Iran Conflict and Strait of Hormuz Disruption 
Google Secures Pentagon AI Deal for Classified Projects 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Celltrion, the South Korean pharmaceutical company, revealed that it had sealed its first deal for shipments of its Rekirona COVID-19 antibody treatment. The firm made the announcement on the supply transaction to Pakistan on Monday, May 10.
Celltrion’s Healthcare division will be managing its overseas business, so it was the company affiliate that signed the deal with Pakistan’s state-run company. The first order is for the shipment of 100,000 vials of Rekirona, which is enough for 30,000 people.
Rekirona receives approval from S. Korea’s drug safety board
As per The Korea Herald, once the vials of the COVID-19 antibody treatment have been delivered, Celltrion will also send its experts to Pakistan so they can train the local medical healthcare providers who have been assigned to administer the treatment.
In February, Celltrion’s Rekirona already received conditional approval from the drug safety board in S. Korea. With that, the medication effectively became the first locally-made treatment for coronavirus.
The treatment has been given to around 2,700 high-risk patients, which include individuals who are over 60 years of age. People with chronic diseases that affect the respiratory system were also administered with Rekirona earlier this year, and the results seem promising, or it will not be approved.
Celltrion already completed the third phase of clinical trials that was conducted in 13 countries with 1,300 volunteers. Aside from S. Korea, some of these nations are the U.S. and Spain. Now, the pharma company is hoping that its Rekirona will be able to help stop the growing number of patients in Pakistan.
Celltrion starts global rollout of its COVID-19 treatment
Yonhap News Agency reported that it is not just Pakistan that will have Celltrion’s Rekirona as there are also ongoing negotiations for supply to Europe, U.S., and more. The exports will start in Pakistan, and the distribution will eventually spread to other nations.
"Talks are also currently underway to export Rekirona to other countries in Europe and South America, as well as India," an official from Celltrion said. Meanwhile, two other pharmaceutical companies are developing similar monoclonal antibody treatment, and these are the US-based Regeneron and Eli Lilly. These are still under clinical tests, so it makes Celltrion the first to make a COVID-19 treatment available globally.
